FAQ audit references
DXM FAQ 1997: selective audit by topic33 audit sources. This is a separate bibliography: these numbers refer to the FAQ audit sources. Each source states what text could be checked.
- William White — historical DXM FAQ — Historical archive
The edition label and date of text version 4.0 and the Erowid HTML archive label (4.0-Y.1) were checked. The archive contains later edits.
- Lutz — DXM metabolism — PubMed abstract
- Rüdesheim — pharmacokinetic model — PubMed abstract
- Capon — CYP2D6 activity — PubMed abstract
- Caudle — CYP2D6 genotype and phenotype — PubMed abstract
- Zawertailo — metabolism and effects — PubMed abstract
- Zawertailo — CYP2D6 inhibition — PubMed abstract
- Xiao — DXM and DXO target binding — Selected paper sections
The abstract, target-binding table and conflict-of-interest disclosure were checked; the authors are employees of the compound’s developer.
- Meoni — DM2 binding sites — PubMed abstract
- Schmidt — sigma-1 structure — PubMed abstract
- Alon — sigma-2 and TMEM97 — PubMed abstract
- Nguyen — mouse model — PubMed abstract
- Carbonaro — DXM effects in humans — PubMed abstract
- Shram — ketamine comparison — PubMed abstract
- Monte — serotonin toxicity — PubMed abstract
- Harada — DXM and moclobemide — PubMed abstract
- Hamelin — diphenhydramine and CYP2D6 — PubMed abstract
- Gillman — serotonin toxicity — PubMed abstract
- Delsym — polistirex label — Official label
The DailyMed label version published on 22 May 2026 was checked for formulation and ingredients.
- Ng — bromism — PubMed abstract
- Carliss — oral DXM in rats — PubMed abstract
- Tran — cellular changes in rats — PubMed abstract
- White — withdrawal of neurotoxicity claims — Historical archive
The author’s 2004 response withdrawing his earlier claims was read.
- Qiu — MRI in DXM dependence — PubMed abstract
- Mutschler — dependence and withdrawal — PubMed abstract
- Olives — prolonged use and tolerance — PubMed abstract
- Chyka — clinical poisoning guideline — PubMed abstract
- Nuedexta — historical FDA label — Official label
The historical 2010 FDA label was read for indication, ingredients and warnings.
- Auvelity — current label — Official label
Indications, ingredients, interactions and mechanism were checked in the label revised in August 2026.
- FDA — new Auvelity indication — Official announcement
The official FDA announcement of 30 April 2026 was read.
- Axsome — AXS-05 program announcement — Audit reference
Listed in the audit bibliography; the primary document was not checked.
- Di Marco — juices and DXM pharmacokinetics — PubMed abstract
- Strauch — grapefruit juice and DXM metabolites — PubMed abstract